IHME

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, May 9, 2024
Accelerometer, Research, Sensor, Wi-Fi, ECG, Cardiology, Biomaterial, Privacy, Boston Scientific, Diagnosis, Skin, IHME, Food, BLE, Flow measurement, Blood pressure, Ageing, Environmental monitoring, Statistics, Diabetes management, Diabetes, CGM, Medicine, World Economic Forum, Wireless, Bluetooth Low Energy, Blood, Temperature, Health care, Component, Wearable, Data, Bluetooth, NFC, Sport, Heart rate, POC, Fitness, Medical device

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points: 
  • Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
  • Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, May 9, 2024
Accelerometer, Research, Sensor, Wi-Fi, ECG, Cardiology, Biomaterial, Privacy, Boston Scientific, Diagnosis, Skin, IHME, Food, BLE, Flow measurement, Blood pressure, Ageing, Environmental monitoring, Statistics, Diabetes management, Diabetes, CGM, Medicine, World Economic Forum, Wireless, Bluetooth Low Energy, Blood, Temperature, Health care, Component, Wearable, Data, Bluetooth, NFC, Sport, Heart rate, POC, Fitness, Medical device

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points: 
  • Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
  • Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
  • Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Global Oxygen Cylinders and Concentrators Market Analysis and Forecasts, 2020-2024 and 2025-2030: Internet of Things (IoT) Connectivity Transforms Oxygen Concentrators into Smart Healthcare Devices - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 11, 2024
Health, Medical Supplies, Medical Devices, USD, Epidemiology, Internet of things, Porter's five forces analysis, Miniaturization, Investment, Chronic obstructive pulmonary disease, SWOT, Skin, Death, Health care, Vital signs, Patient safety, Mask, Incidence, Sleep apnea, Patient, Asthma, Prevalence, IHME, Medication, COPD, Medical device

The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.

Key Points: 
  • The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.
  • The Oxygen Cylinders and Concentrators Market is expected to continue growing as the global population ages and the prevalence of respiratory diseases increases, driving the need for effective oxygen therapy solutions.
  • As the global population ages and environmental factors contribute to respiratory health issues, the need for oxygen cylinders and concentrators continues to grow.
  • Technological advancements in portable oxygen cylinders and concentrators have transformed respiratory care, offering greater convenience, mobility, and usability for patients.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023
Janus, Partnership, RA, Astellas Pharma, Prevalence, JAK, Disease, GBD, Menarini, Inflammation, Institute for Health Metrics and Evaluation, Person, Pain, Patient, Rheumatoid arthritis, Joint, Diagnosis, Castleman Disease Collaborative Network, IHME, Pharmaceutical industry, Tablet

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Retrieved on: 
Wednesday, September 13, 2023
Janus, Partnership, RA, Astellas Pharma, Prevalence, JAK, Disease, GBD, Menarini, Inflammation, Institute for Health Metrics and Evaluation, Person, Pain, Patient, Rheumatoid arthritis, Joint, Diagnosis, Castleman Disease Collaborative Network, IHME, Pharmaceutical industry, Tablet

Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.

Key Points: 
  • Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
  • Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments.
  • In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®.
  • Menarini will have an option to extend the rights to select South-East Asian markets.

Study Finds Significantly More Adults Living with Diabetic Retinopathy in the United States than Previously Estimated

Retrieved on: 
Friday, June 16, 2023
Retina, Microsoft PowerPoint, University, Prevalence, Diabetes, Education, Visual impairment, Diabetic retinopathy, Centers for Disease Control and Prevention, Public, Policy, Eye, DR, Brain, Cell, Social media, Person, CDC, Vision, Ophthalmology, Institute for Health Metrics and Evaluation, Public health, NORC, Patient, Bleeding, Risk, University of Washington Department of Global Health, NORC at the University of Chicago, Mortality, Paratriathlon, MPH, White, IHME, Safety, Pharmaceutical industry, Medical device, Nursing, Soft drink, Toy, Dietary supplement, Doctor of Philosophy, JAMA Ophthalmology

CHICAGO, June 16, 2023 /PRNewswire-PRWeb/ --  A new study published today in JAMA Ophthalmology, "Prevalence of Diabetic Retinopathy in the US in 2021," found that in 2021, an estimated 9.6 million people in the United States (26.4 percent of those with diabetes) had diabetic retinopathy (DR), and 1.84 million people (5.1 percent of those with diabetes) had vision-threatening diabetic retinopathy (VTDR). The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004. VTDR has also almost doubled since last estimated in 2004.

Key Points: 
  • New study finds that nearly 10 million people in the US with diabetes have diabetic retinopathy.
  • The number of people aged 40 years and older living with diabetes-related eye disease more than doubled since prevalence was last estimated in 2004.
  • The study is the first of its kind to estimate the prevalence of DR and VTDR in people younger than 40 years.
  • For more information on the "The Prevalence of Diabetic Retinopathy in the United States In 2021" study or the VEHSS, visit https://www.cdc.gov/visionhealth/vehss/ .

Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting

Retrieved on: 
Monday, April 24, 2023
Mental Health, Health, Telemedicine, Virtual Medicine, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, DSM-IV codes, Spinal muscular atrophy, Survival, Multiple sclerosis, Science, Patient, Nervous system, Ageing, Policy, IHME, Disease, Maintenance, Cleveland Clinic, University, Disability, Cardiovascular disease, Dementia, Brain, NMOSD, Research, Satralizumab, RO, RMS, RRMS, Cleveland, Immunodeficiency, Phase, Death, Safety, Huntington's disease, Abstract, Natural history, COVID-19, Multimedia, ROG, Brainpower, Neuroscience, Myasthenia gravis, Cancer, EMPOWER, Angelman syndrome, SMA, Experience, Telehealth, Partnership, Central nervous system, AAN, American Academy, Digital technology, Annual general meeting, Neuromyelitis optica spectrum disorder, Tenecteplase, AD, Pharmaceutical industry, Medical imaging, Risdiplam, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is announcing three new partnerships focused on improving brain health outcomes.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is announcing three new partnerships focused on improving brain health outcomes.
  • “With that in mind, we are committed to developing and delivering new medicines that address areas of highest need in neuroscience.
  • See AAN oral presentation details on Genentech’s telehealth pilot with Cleveland Clinic here , Tuesday, April 25 at 3:54 p.m.
  • To meet the needs of people living with brain health conditions, Genentech is continuing to grow and advance its pipeline, with key areas of focus in neuroimmunologic, neuromuscular, neurodegenerative and neurodevelopmental diseases.

Atlanta Neuroscience Foundation Marks World Neuroscience Day with Keynote Speaker Mark Richt, Former UGA Football Coach

Retrieved on: 
Tuesday, April 18, 2023
Hyatt, Optimism, Education, Culture, AAN, Roche, Health equity, Health, Quality of life, Hope, American Academy, Microsoft, UGA, Parkinson's Foundation, Research, DSM-IV codes, Life expectancy, Parkinson, MS, Alzheimer's disease, Institute for Health Metrics and Evaluation, Parkinson's disease, Epilepsy Foundation, Gates Ventures, Diagnosis, American Academy of Neurology, ANF, IHME, Past // Present // Future, Caregiver, Pharmaceutical industry, Nursing, Epilepsy

ATLANTA, April 18, 2023 /PRNewswire/ -- Mark Richt, former UGA football coach, will be the keynote speaker and open the conference with a conversation highlighting his journey living with Parkinson's.

Key Points: 
  • ATLANTA, April 18, 2023 /PRNewswire/ -- Mark Richt, former UGA football coach, will be the keynote speaker and open the conference with a conversation highlighting his journey living with Parkinson's.
  • Following the opening general assembly, attendees will have access to neurology specialists addressing medical advancements, research, education, and patient outcomes.
  • World Neuroscience Day is an awareness campaign and conference created by the Atlanta Neuroscience Foundation (ANF), an Atlanta-based 501c3.
  • World Neuroscience Day conference will be held Saturday, May 6, 2023, at Grand Hyatt Hotel-Buckhead from 8:00 am to 4:00 pm.

New study reveals half of malnutrition-related deaths in those with clefts could be prevented

Retrieved on: 
Friday, October 7, 2022
Medical school, Risk, Disease, Organization, IHME, Mortality, Institute for Health Metrics and Evaluation, Institute, Death, University, University of Washington Department of Global Health, Malnutrition, Smile, MD, CEO, Cleft lip and cleft palate, Child, Hearing, Development, School, Dentistry, Birth control, Medicine

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- In a new report released today, World Smile Day, Smile Train and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington's School of Medicine find that nearly half of cleft-related malnutrition deaths globally in children under 5 could be prevented with access to adequate nutrition and surgical treatment.

Key Points: 
  • The report provides a first-of-its-kind look at the devastating impact of orofacial clefts over two decades, 2000 to 2020.
  • The report synthesized two sets of data, one from Smile Train Express and the other IHME's Global Burden of Disease Modeling demographic group.
  • If children with clefts did not experience higher rates of undernutrition, as many as 21,000 deaths worldwide could be averted with intervention.
  • Over the past 20 years, the number of children born with clefts under the age of 5 has failed to decline significantly.

New study reveals half of malnutrition-related deaths in those with clefts could be prevented

Retrieved on: 
Friday, October 7, 2022
Medical school, Risk, Disease, Organization, IHME, Mortality, Institute for Health Metrics and Evaluation, Institute, Death, University, University of Washington Department of Global Health, Malnutrition, Smile, MD, CEO, Cleft lip and cleft palate, Child, Hearing, Development, School, Dentistry, Birth control, Medicine

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- In a new report released today, World Smile Day, Smile Train and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington's School of Medicine find that nearly half of cleft-related malnutrition deaths globally in children under 5 could be prevented with access to adequate nutrition and surgical treatment.

Key Points: 
  • The report provides a first-of-its-kind look at the devastating impact of orofacial clefts over two decades, 2000 to 2020.
  • The report synthesized two sets of data, one from Smile Train Express and the other IHME's Global Burden of Disease Modeling demographic group.
  • If children with clefts did not experience higher rates of undernutrition, as many as 21,000 deaths worldwide could be averted with intervention.
  • Over the past 20 years, the number of children born with clefts under the age of 5 has failed to decline significantly.